2024-11-08 - Analysis Report
## Abbott Laboratories (ABT) Stock Analysis

**1. Performance Relative to S&P 500 (VOO)**

Abbott Laboratories (ABT), a healthcare company specializing in pharmaceuticals, medical devices, nutrition, and diagnostics, has underperformed the S&P 500 (VOO) over the last period. While ABT has seen a cumulative return of 108.62%, VOO has achieved a 139.88% return, resulting in a -31.26% difference. This difference places ABT at the 11.74th percentile relative to its historical performance range against VOO. 

**Alpha and Beta Analysis:**

* **Alpha:** ABT generally exhibited positive alpha, indicating it outperformed the market. This is particularly evident during 2016-2018, 2017-2019, and 2018-2020. However, recent periods (2021-2023 and 2022-2024) show negative alpha, suggesting underperformance.
* **Beta:** ABT has generally displayed a beta close to or slightly above 1, suggesting similar volatility compared to the market. However, recent periods show a lower beta (0.7), indicating less volatility than the market.

**2. Recent Price Movement:**

* **Closing Price:** $116.8 (Last Market: $115.18)
* **5-day Moving Average:** $116.83
* **20-day Moving Average:** $116.35
* **60-day Moving Average:** $114.61

ABT is currently trading slightly above its 5-day, 20-day, and 60-day moving averages. This suggests potential upward momentum.

**3. Technical Indicators:**

* **RSI:** 47.07 - This suggests that ABT is currently in a neutral territory, neither overbought nor oversold.
* **PPO:** 0.07 - This indicates a weak but positive momentum, suggesting potential for further upside.
* **Delta_Previous_Relative_Divergence:** -3.14 (-) - A recent negative change in the relative divergence, indicating short-term bearish pressure. 
* **Expected Return:** 0.0% - This indicates that ABT is expected to generate similar returns to the S&P 500 over the next 2 years.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-10-31 | 0.94 | $10.63 B |
| 2024-07-31 | 0.74 | $10.38 B |
| 2024-05-02 | 0.7 | $9.96 B |
| 2023-11-01 | 0.82 | $10.14 B |
| 2024-10-31 | 0.82 | $10.14 B |

ABT has shown stable revenue growth in recent quarters. However, EPS has been fluctuating. The most recent earnings report for the quarter ending October 31, 2024, saw EPS of $0.94, exceeding analysts' expectations. This positive earnings surprise may contribute to a short-term upward price movement.

**5. Financial Information:**

**Revenue and Profitability**

| Quarter | Revenue | Profit Margin |
|---|---|---|
| 2024-09-30 | $10.63B | 55.83% |
| 2024-06-30 | $10.38B | 55.64% |
| 2024-03-31 | $9.96B | 55.21% |
| 2023-12-31 | $10.24B | 55.51% |
| 2023-09-30 | $10.14B | 54.60% |

**Capital and Profitability**

| Quarter | Equity | ROE |
|---|---|---|
| 2024-09-30 | $39.80B | 4.14% |
| 2024-06-30 | $39.32B | 3.31% |
| 2024-03-31 | $38.81B | 3.16% |
| 2023-12-31 | $38.60B | 4.13% |
| 2023-09-30 | $37.48B | 3.83% |

ABT demonstrates strong profitability with consistently high profit margins. However, ROE fluctuates, suggesting potential fluctuations in profitability.

**6. News and Recent Issues:**

* **Recent Earnings News:** ABT's most recent earnings report released on November 01, 2024, was a positive surprise, exceeding analyst expectations. This positive news was well-received by the market, contributing to the slight upward price movement. 
* **Recent Market Outlook:** Analyst sentiment towards ABT remains positive, highlighting its strong track record and diversified business model. However, some analysts remain cautious about its growth potential, citing concerns around competition and regulatory pressures within the healthcare sector.
* **Performance Highlights:** ABT's stock performance has been relatively stable, with consistent dividends and steady revenue growth.  The company has also successfully navigated recent market volatility, demonstrating resilience and a solid financial foundation. 

**7. Summary:**

ABT remains a solid investment with a long history of reliable performance. Despite recent underperformance relative to the S&P 500, its strong earnings report and positive market outlook suggest potential for future upside. The stock's current technical indicators are neutral to slightly positive, suggesting potential for further upward movement. However, it is important to monitor the company's progress and remain aware of potential risks within the healthcare industry.

**8. Recommendation:**

Investors with a long-term investment horizon may consider adding ABT to their portfolios. While the stock may not outperform the market significantly, it offers a stable and reliable investment opportunity with consistent dividends and a solid financial position. However, investors seeking significant growth potential may consider other stocks within the healthcare sector.

**Note:** This analysis is based on the provided data and may not reflect all relevant information for a comprehensive investment decision. It is essential to conduct thorough research and consult with a financial advisor before making any investment decisions.